Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C

Neal D. Freedman, James E. Everhart, Karen L. Lindsay, Marc G. Ghany, Teresa M. Curto, Mitchell L. Shiffman, William M. Lee, Anna S. Lok, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, John C. Hoefs, Jules L. Dienstag, Chihiro Morishima, Christian C. Abnet, Rashmi Sinha

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C-related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 ormore cups/day (P-trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression.

Original languageEnglish (US)
Pages (from-to)1360-1369
Number of pages10
JournalHepatology
Volume50
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Coffee
Chronic Hepatitis C
Disease Progression
Liver Diseases
Hepatitis C
Fibrosis
Tea
Biopsy
Ribavirin
alpha-Fetoproteins
Aspartate Aminotransferases
Alanine Transaminase
Liver Cirrhosis
Drinking
Antiviral Agents
Albumins
Chronic Disease
Therapeutics
Prospective Studies
Confidence Intervals

ASJC Scopus subject areas

  • Hepatology

Cite this

Freedman, N. D., Everhart, J. E., Lindsay, K. L., Ghany, M. G., Curto, T. M., Shiffman, M. L., ... Sinha, R. (2009). Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology, 50(5), 1360-1369. https://doi.org/10.1002/hep.23162

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. / Freedman, Neal D.; Everhart, James E.; Lindsay, Karen L.; Ghany, Marc G.; Curto, Teresa M.; Shiffman, Mitchell L.; Lee, William M.; Lok, Anna S.; Di Bisceglie, Adrian M.; Bonkovsky, Herbert L.; Hoefs, John C.; Dienstag, Jules L.; Morishima, Chihiro; Abnet, Christian C.; Sinha, Rashmi.

In: Hepatology, Vol. 50, No. 5, 2009, p. 1360-1369.

Research output: Contribution to journalArticle

Freedman, ND, Everhart, JE, Lindsay, KL, Ghany, MG, Curto, TM, Shiffman, ML, Lee, WM, Lok, AS, Di Bisceglie, AM, Bonkovsky, HL, Hoefs, JC, Dienstag, JL, Morishima, C, Abnet, CC & Sinha, R 2009, 'Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C', Hepatology, vol. 50, no. 5, pp. 1360-1369. https://doi.org/10.1002/hep.23162
Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009;50(5):1360-1369. https://doi.org/10.1002/hep.23162
Freedman, Neal D. ; Everhart, James E. ; Lindsay, Karen L. ; Ghany, Marc G. ; Curto, Teresa M. ; Shiffman, Mitchell L. ; Lee, William M. ; Lok, Anna S. ; Di Bisceglie, Adrian M. ; Bonkovsky, Herbert L. ; Hoefs, John C. ; Dienstag, Jules L. ; Morishima, Chihiro ; Abnet, Christian C. ; Sinha, Rashmi. / Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. In: Hepatology. 2009 ; Vol. 50, No. 5. pp. 1360-1369.
@article{b8b3ef81628440bca9aec5ad227a6699,
title = "Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C",
abstract = "Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C-related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 ormore cups/day (P-trend = 0.0011). Relative risks (95{\%} confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression.",
author = "Freedman, {Neal D.} and Everhart, {James E.} and Lindsay, {Karen L.} and Ghany, {Marc G.} and Curto, {Teresa M.} and Shiffman, {Mitchell L.} and Lee, {William M.} and Lok, {Anna S.} and {Di Bisceglie}, {Adrian M.} and Bonkovsky, {Herbert L.} and Hoefs, {John C.} and Dienstag, {Jules L.} and Chihiro Morishima and Abnet, {Christian C.} and Rashmi Sinha",
year = "2009",
doi = "10.1002/hep.23162",
language = "English (US)",
volume = "50",
pages = "1360--1369",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C

AU - Freedman, Neal D.

AU - Everhart, James E.

AU - Lindsay, Karen L.

AU - Ghany, Marc G.

AU - Curto, Teresa M.

AU - Shiffman, Mitchell L.

AU - Lee, William M.

AU - Lok, Anna S.

AU - Di Bisceglie, Adrian M.

AU - Bonkovsky, Herbert L.

AU - Hoefs, John C.

AU - Dienstag, Jules L.

AU - Morishima, Chihiro

AU - Abnet, Christian C.

AU - Sinha, Rashmi

PY - 2009

Y1 - 2009

N2 - Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C-related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 ormore cups/day (P-trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression.

AB - Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C-related liver disease. Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on protocol biopsies. At baseline, higher coffee consumption was associated with less severe steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score, and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 ormore cups/day (P-trend = 0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1 cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes. Conclusion: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression.

UR - http://www.scopus.com/inward/record.url?scp=72949092282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949092282&partnerID=8YFLogxK

U2 - 10.1002/hep.23162

DO - 10.1002/hep.23162

M3 - Article

VL - 50

SP - 1360

EP - 1369

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -